

# Daniel T O'connor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11896624/publications.pdf>

Version: 2024-02-01

197  
papers

10,076  
citations

30070

54  
h-index

45317

90  
g-index

200  
all docs

200  
docs citations

200  
times ranked

8596  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chromogranin A pathway: from pathogenic molecule to renal disease. <i>Journal of Hypertension</i> , 2020, 38, 456-466.	0.5	3
2	A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function. <i>Scientific Reports</i> , 2019, 9, 5055.	3.3	6
3	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. <i>Nature Communications</i> , 2017, 8, 15805.	12.8	95
4	iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. <i>Stem Cell Reports</i> , 2017, 8, 1086-1100.	4.8	147
5	Identification of novel loci affecting circulating chromogranins and related peptides. <i>Human Molecular Genetics</i> , 2016, 26, ddw380.	2.9	13
6	Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system. <i>BMC Medical Genetics</i> , 2016, 17, 21.	2.1	14
7	Molecular Mechanism for Hypertensive Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1816-1825.	6.1	13
8	Pancreastatin-Dependent Inflammatory Signaling Mediates Obesity-Induced Insulin Resistance. <i>Diabetes</i> , 2015, 64, 104-116.	0.6	59
9	Heritability of Biomarkers of Oxidized Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1704-1711.	2.4	44
10	Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. <i>Psychoneuroendocrinology</i> , 2015, 51, 459-471.	2.7	147
11	Chromogranin B: intra- and extra-cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms. <i>Journal of Neurochemistry</i> , 2014, 129, 48-59.	3.9	15
12	Nicotinic Acetylcholine Receptors in Glucose Homeostasis: The Acute Hyperglycemic and Chronic Insulin-Sensitive Effects of Nicotine Suggest Dual Opposing Roles of the Receptors in Male Mice. <i>Endocrinology</i> , 2014, 155, 3793-3805.	2.8	31
13	Assessment of Plasma C-Reactive Protein as a Biomarker of Posttraumatic Stress Disorder Risk. <i>JAMA Psychiatry</i> , 2014, 71, 423.	11.0	290
14	Heart Rate Variability Characteristics in a Large Group of Active-Duty Marines and Relationship to Posttraumatic Stress. <i>Psychosomatic Medicine</i> , 2014, 76, 292-301.	2.0	80
15	The catecholamine biosynthetic enzyme dopamine $\beta$ -hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter. <i>Human Molecular Genetics</i> , 2014, 23, 6375-6384.	2.9	25
16	Human Heart Rate. <i>Journal of the American College of Cardiology</i> , 2014, 63, 358-368.	2.8	11
17	Genetic Implication of a Novel Thiamine Transporter in Human Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1542-1555.	2.8	36
18	Discovery of a Novel Target for the Dysglycemic Chromogranin A Fragment Pancreastatin: Interaction with the Chaperone GRP78 to Influence Metabolism. <i>PLoS ONE</i> , 2014, 9, e84132.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: Virtual screening and functional testing identify novel small molecule therapeutics of hypertension. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5855-5869.	3.0	13
20	MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. <i>Human Molecular Genetics</i> , 2013, 22, 3624-3640.	2.9	46
21	Granins and Catecholamines. <i>Advances in Pharmacology</i> , 2013, 68, 93-113.	2.0	7
22	Genetic variation at the delta $\alpha$ -sarcoglycan ( <i>SGCD</i> ) locus elevates heritable sympathetic nerve activity in human twin pairs. <i>Journal of Neurochemistry</i> , 2013, 127, 750-761.	3.9	2
23	Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. <i>Psychoneuroendocrinology</i> , 2013, 38, 2378-2382.	2.7	27
24	Heredity and cardiometabolic risk. <i>Journal of Hypertension</i> , 2013, 31, 123-133.	0.5	8
25	Association of Functional Kallikrein-1 Promoter Polymorphisms and Acute Kidney Injury: A Case-Control and Longitudinal Cohort Study. <i>Nephron Clinical Practice</i> , 2013, 122, 107-113.	2.3	5
26	Heritable Influence of DBH on Adrenergic and Renal Function: Twin and Disease Studies. <i>PLoS ONE</i> , 2013, 8, e82956.	2.5	12
27	Genetic Variation Within a Metabolic Motif in the Chromogranin A Promoter: Pleiotropic Influence on Cardiometabolic Risk Traits in Twins. <i>American Journal of Hypertension</i> , 2012, 25, 29-40.	2.0	6
28	Integrated Computational and Experimental Analysis of the Neuroendocrine Transcriptome in Genetic Hypertension Identifies Novel Control Points for the Cardiometabolic Syndrome. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 430-440.	5.1	6
29	Catestatin (Chromogranin A352-372) and Novel Effects on Mobilization of Fat from Adipose Tissue through Regulation of Adrenergic and Leptin Signaling. <i>Journal of Biological Chemistry</i> , 2012, 287, 23141-23151.	3.4	63
30	Genes and environment. <i>Journal of Hypertension</i> , 2012, 30, 1961-1969.	0.5	13
31	Novel Peptide Isomer Strategy for Stable Inhibition of Catecholamine Release. <i>Hypertension</i> , 2012, 60, 1552-1559.	2.7	31
32	Biomarkers of PTSD: Neuropeptides and immune signaling. <i>Neuropharmacology</i> , 2012, 62, 663-673.	4.1	162
33	Autonomic and Hemodynamic Origins of Pre-Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2206-2216.	2.8	36
34	Neuropeptide Y (NPY). <i>Journal of the American College of Cardiology</i> , 2012, 60, 1678-1689.	2.8	22
35	The Protein Architecture of Human Secretory Vesicles Reveals Differential Regulation of Signaling Molecule Secretion by Protein Kinases. <i>PLoS ONE</i> , 2012, 7, e41134.	2.5	11
36	Predictors of Risk and Resilience for Posttraumatic Stress Disorder Among Ground Combat Marines: Methods of the Marine Resiliency Study. <i>Preventing Chronic Disease</i> , 2012, 9, E97.	3.4	66

#	ARTICLE	IF	CITATIONS
37	Systematic polymorphism discovery after genome-wide identification of potential susceptibility loci in a hereditary rodent model of human hypertension. <i>Blood Pressure</i> , 2011, 20, 222-231.	1.5	10
38	Contemporary approaches to genetic influences on hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 23-30.	2.0	9
39	Catecholamine biosynthesis and secretion: physiological and pharmacological effects of secretin. <i>Cell and Tissue Research</i> , 2011, 345, 87-102.	2.9	4
40	Catecholamine Storage Vesicles: Role of Core Protein Genetic Polymorphisms in Hypertension. <i>Current Hypertension Reports</i> , 2011, 13, 36-45.	3.5	16
41	A Common Genetic Variant in the 3' UTR of Vacuolar H <sup>+</sup> -ATPase <i>ATP6V0A1</i> Creates a Micro-RNA Motif to Alter Chromogranin A Processing and Hypertension Risk. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 381-389.	5.1	31
42	Human Dopamine $\beta$ -Hydroxylase Promoter Variant Alters Transcription in Chromaffin Cells, Enzyme Secretion, and Blood Pressure. <i>American Journal of Hypertension</i> , 2011, 24, 24-32.	2.0	21
43	Proteomic Analysis Yields an Unexpected <i>Trans</i> -Acting Point in Control of the Human Sympathochromaffin Phenotype. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 437-445.	5.1	2
44	Naturally Occurring Variations in the Human Cholinesterase Genes: Heritability and Association with Cardiovascular and Metabolic Traits. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 125-133.	2.5	22
45	Early Inflammatory and Metabolic Changes in Association With <i>AGTR1</i> Polymorphisms in Prehypertensive Subjects. <i>American Journal of Hypertension</i> , 2011, 24, 225-233.	2.0	22
46	Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure. <i>Journal of Hypertension</i> , 2010, 28, 76-86.	0.5	48
47	Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. <i>Journal of Hypertension</i> , 2010, 28, 817-825.	0.5	31
48	Long human <i>CHGA</i> flanking chromosome 14 sequence required for optimal BAC transgenic rescue of disease phenotypes in the mouse <i>Chga</i> knockout. <i>Physiological Genomics</i> , 2010, 41, 91-101.	2.3	12
49	Neuropeptidomic Components Generated by Proteomic Functions in Secretory Vesicles for Cell-Cell Communication. <i>AAPS Journal</i> , 2010, 12, 635-645.	4.4	23
50	Conserved regulatory motifs at phenylethanolamine N-methyltransferase (PNMT) are disrupted by common functional genetic variation: an integrated computational/experimental approach. <i>Mammalian Genome</i> , 2010, 21, 195-204.	2.2	6
51	Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin ( <i>Chga364-384</i> ). <i>Cell and Tissue Research</i> , 2010, 342, 353-361.	2.9	48
52	Human Tyrosine Hydroxylase Natural Allelic Variation: Influence on Autonomic Function and Hypertension. <i>Cellular and Molecular Neurobiology</i> , 2010, 30, 1391-1394.	3.3	16
53	Naturally Occurring Genetic Variants in Human Chromogranin A (CHGA) Associated with Hypertension as well as Hypertensive Renal Disease. <i>Cellular and Molecular Neurobiology</i> , 2010, 30, 1395-1400.	3.3	9
54	Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. <i>Regulatory Peptides</i> , 2010, 165, 63-70.	1.9	24

#	ARTICLE	IF	CITATIONS
55	Reprint of: Catestatin: A multifunctional peptide from chromogranin A. <i>Regulatory Peptides</i> , 2010, 165, 52-62.	1.9	16
56	Hypertension as a Maladaptive "Fight-or-Flight" Response?: Confirmatory Molecular Genetic Evidence From the Human Catecholamine Biosynthetic Pathway. <i>American Journal of Hypertension</i> , 2010, 23, 1250-1251.	2.0	0
57	Phenylethanolamine N-Methyltransferase Gene Polymorphisms and Adverse Outcomes in Acute Kidney Injury. <i>Nephron Clinical Practice</i> , 2010, 114, c253-c259.	2.3	19
58	Human Tyrosine Hydroxylase Natural Genetic Variation. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 187-198.	5.1	28
59	Role of Reactive Oxygen Species in Hyperadrenergic Hypertension. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 414-425.	5.1	42
60	Pro-hormone Secretogranin II Regulates Dense Core Secretory Granule Biogenesis in Catecholaminergic Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 10030-10043.	3.4	38
61	Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in Humans <i>In Vivo</i> . <i>Clinical and Experimental Hypertension</i> , 2010, 32, 278-287.	1.3	79
62	Progression of Chronic Kidney Disease: Adrenergic Genetic Influence on Glomerular Filtration Rate Decline in Hypertensive Nephrosclerosis. <i>American Journal of Nephrology</i> , 2010, 32, 23-30.	3.1	14
63	Common Charge-Shift Mutation Glu65Lys in K <sup>+</sup> Channel $\beta$ 1-Subunit KCNMB1: Pleiotropic Consequences for Glomerular Filtration Rate and Progressive Renal Disease. <i>American Journal of Nephrology</i> , 2010, 32, 414-424.	3.1	14
64	Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. <i>Physiological Genomics</i> , 2010, 40, 195-207.	2.3	16
65	Chromogranin A and the Autonomic System: Decomposition of Heart Rate Variability and Rescue by Its Catestatin Fragment. <i>Endocrinology</i> , 2010, 151, 2760-2768.	2.8	34
66	Urocortin 2 Lowers Blood Pressure and Reduces Plasma Catecholamine Levels in Mice with Hyperadrenergic Activity. <i>Endocrinology</i> , 2010, 151, 4820-4829.	2.8	10
67	Common Functional Genetic Variants in Catecholamine Storage Vesicle Protein Promoter Motifs Interact to Trigger Systemic Hypertension. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1463-1475.	2.8	20
68	Isoprostane, an "Intermediate Phenotype" for Oxidative Stress. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1338-1350.	2.8	12
69	Genetic Covariance Between $\beta$ -Glutamyl Transpeptidase and Fatty Liver Risk Factors: Role of $\beta$ 2-Adrenergic Receptor Genetic Variation in Twins. <i>Gastroenterology</i> , 2010, 139, 836-845.e1.	1.3	53
70	Proteomics of Dense Core Secretory Vesicles Reveal Distinct Protein Categories for Secretion of Neuroeffectors for Cell-Cell Communication. <i>Journal of Proteome Research</i> , 2010, 9, 5002-5024.	3.7	48
71	Mass Spectrometry-Based Neuropeptidomics of Secretory Vesicles from Human Adrenal Medullary Pheochromocytoma Reveals Novel Peptide Products of Prohormone Processing. <i>Journal of Proteome Research</i> , 2010, 9, 5065-5075.	3.7	29
72	Neuroendocrine Nicotinic Receptor Activation Increases Susceptibility to Bacterial Infections by Suppressing Antimicrobial Peptide Production. <i>Cell Host and Microbe</i> , 2010, 7, 277-289.	11.0	69

#	ARTICLE	IF	CITATIONS
73	Catestatin: A multifunctional peptide from chromogranin A. <i>Regulatory Peptides</i> , 2010, 162, 33-43.	1.9	102
74	Genome-wide case/control studies in hypertension: only the "tip of the iceberg". <i>Journal of Hypertension</i> , 2010, 28, 1115-1123.	0.5	26
75	A Novel Pathway of Insulin Sensitivity in Chromogranin A Null Mice. <i>Journal of Biological Chemistry</i> , 2009, 284, 28498-28509.	3.4	87
76	Chromogranin A Regulates Renal Function by Triggering Weibel-Palade Body Exocytosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1623-1632.	6.1	24
77	Autonomic Function in Hypertension. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 46-56.	5.1	26
78	Global Disturbances in Autonomic Function Yield Cardiovascular Instability and Hypertension in the Chromogranin A Null Mouse. <i>Endocrinology</i> , 2009, 150, 5027-5035.	2.8	60
79	Cathepsin L Colocalizes with Chromogranin A in Chromaffin Vesicles to Generate Active Peptides. <i>Endocrinology</i> , 2009, 150, 3547-3557.	2.8	67
80	Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits. <i>Kidney International</i> , 2009, 76, 1070-1080.	5.2	13
81	Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3677-3686.	0.7	11
82	Complex Renal Traits: Role of Adrenergic Genetic Polymorphism. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1172-1174.	6.1	1
83	Natural Variation within the Neuronal Nicotinic Acetylcholine Receptor Cluster on Human Chromosome 15q24: Influence on Heritable Autonomic Traits in Twin Pairs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 419-428.	2.5	8
84	Neuropeptide Y1 Receptor NPY1R. <i>Journal of the American College of Cardiology</i> , 2009, 54, 944-954.	2.8	28
85	Adrenergic Polymorphism and the Human Stress Response. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 282-296.	3.8	18
86	The Neuroendocrine Peptide Catestatin Is a Cutaneous Antimicrobial and Induced in the Skin after Injury. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1525-1534.	0.7	103
87	Naturally Occurring Human Genetic Variation in the 5'-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent Fashion. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1468-1481.	2.8	44
88	Hereditary Determinants of Human Hypertension. <i>Hypertension</i> , 2008, 51, 1456-1464.	2.7	53
89	Genetic Variation Within Adrenergic Pathways Determines In Vivo Effects of Presynaptic Stimulation in Humans. <i>Circulation</i> , 2008, 117, 517-525.	1.6	18
90	The Crucial Role of Chromogranins in Storage and Exocytosis Revealed Using Chromaffin Cells from Chromogranin A Null Mouse. <i>Journal of Neuroscience</i> , 2008, 28, 3350-3358.	3.6	120

#	ARTICLE	IF	CITATIONS
91	Heritability and Genome-Wide Linkage in US and Australian Twins Identify Novel Genomic Regions Controlling Chromogranin A. <i>Circulation</i> , 2008, 118, 247-257.	1.6	79
92	Chromogranin A Polymorphisms Are Associated With Hypertensive Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 600-614.	6.1	58
93	Proteolytic Cleavage of Human Chromogranin A Containing Naturally Occurring Catestatin Variants: Differential Processing at Catestatin Region by Plasmin. <i>Endocrinology</i> , 2008, 149, 749-757.	2.8	50
94	The trans-Golgi Proteins SCLIP and SCG10 Interact with Chromogranin A To Regulate Neuroendocrine Secretion. <i>Biochemistry</i> , 2008, 47, 7167-7178.	2.5	21
95	Heredity of Endothelin Secretion. <i>Circulation</i> , 2007, 115, 2282-2291.	1.6	18
96	Population-Based Sample Reveals Gene-Gender Interactions in Blood Pressure in White Americans. <i>Hypertension</i> , 2007, 49, 96-106.	2.7	107
97	Renal Albumin Excretion. <i>Hypertension</i> , 2007, 49, 1015-1031.	2.7	50
98	Cox-2 Promotes Chromogranin A Expression and Bioactivity: Evidence for a Prostaglandin E2-Dependent Mechanism and the Involvement of a Proximal Cyclic Adenosine 5'-Monophosphate-Responsive Element. <i>Endocrinology</i> , 2007, 148, 4310-4317.	2.8	6
99	Whole-Genome Analysis of Sporadic Amyotrophic Lateral Sclerosis. <i>New England Journal of Medicine</i> , 2007, 357, 775-788.	27.0	234
100	Catecholamine Release-Inhibitory Peptide Catestatin (Chromogranin A 352-372). <i>Circulation</i> , 2007, 115, 2271-2281.	1.6	105
101	An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension. <i>Human Molecular Genetics</i> , 2007, 16, 1752-1764.	2.9	29
102	Granulogenesis in Non-neuroendocrine COS-7 Cells Induced by EGFP-tagged Chromogranin A Gene Transfection: Identical and Distinct Distribution of CgA and EGFP. <i>Journal of Histochemistry and Cytochemistry</i> , 2007, 55, 487-493.	2.5	12
103	C-reactive protein, an "intermediate phenotype" for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/ $\beta$ 2-adrenergic pathway loci. <i>Journal of Hypertension</i> , 2007, 25, 329-343.	0.5	88
104	Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. <i>Journal of Hypertension</i> , 2007, 25, 2082-2092.	0.5	43
105	Biogenesis of the Secretory Granule: Chromogranin A Coiled-Coil Structure Results in Unusual Physical Properties and Suggests a Mechanism for Granule Core Condensation. <i>Biochemistry</i> , 2007, 46, 10999-11012.	2.5	34
106	Tyrosine Hydroxylase, the Rate-Limiting Enzyme in Catecholamine Biosynthesis. <i>Circulation</i> , 2007, 116, 993-1006.	1.6	89
107	Catecholamines, Pheochromocytoma, and Hypertension: Genomic Insights. , 2007, , 895-911.		0
108	Primary culture of bovine chromaffin cells. <i>Nature Protocols</i> , 2007, 2, 1248-1253.	12.0	32



#	ARTICLE	IF	CITATIONS
109	Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. <i>Journal of Clinical Investigation</i> , 2007, 117, 2658-2671.	8.2	87
110	Polymorphisms of $\beta$ 1a and $\beta$ 1b $\alpha$ -adrenergic receptors help identify patients with arterial hypertension. <i>FASEB Journal</i> , 2007, 21, A422.	0.5	0
111	Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. <i>Physiological Genomics</i> , 2006, 25, 470-479.	2.3	18
112	The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. <i>Journal of Hypertension</i> , 2006, 24, 895-904.	0.5	35
113	Catecholamine storage vesicles and the metabolic syndrome: the role of the chromogranin A fragment pancreastatin. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 621-633.	4.4	31
114	Molecular basis of neuroendocrine cell type-specific expression of the chromogranin $\beta$ gene: crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. <i>Journal of Neurochemistry</i> , 2006, 99, 119-133.	3.9	27
115	Butyrylcholinesterase: Association with the Metabolic Syndrome and Identification of 2 Gene Loci Affecting Activity. <i>Clinical Chemistry</i> , 2006, 52, 1014-1020.	3.2	56
116	Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Gene in Normotensives and Hypertensives. <i>Hypertension</i> , 2006, 47, 415-420.	2.7	68
117	Early Phenotypic Changes in Hypertension. <i>Hypertension</i> , 2006, 47, 331-333.	2.7	20
118	Rho Kinase Polymorphism Influences Blood Pressure and Systemic Vascular Resistance in Human Twins. <i>Hypertension</i> , 2006, 47, 937-947.	2.7	70
119	Secretory Granule Biogenesis in Sympathoadrenal Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 38038-38051.	3.4	51
120	Human response to $\beta$ -adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 388-403.	4.7	25
121	Assessment of multiple displacement amplification for polymorphism discovery and haplotype determination at a highly polymorphic locus, MC1R. <i>Human Mutation</i> , 2005, 26, 145-152.	2.5	29
122	Role of H <sup>+</sup> -ATPase-mediated Acidification in Sorting and Release of the Regulated Secretory Protein Chromogranin A. <i>Journal of Biological Chemistry</i> , 2005, 280, 3885-3897.	3.4	71
123	Genetic Variation at the Human $\beta$ 2B -Adrenergic Receptor Locus. <i>Hypertension</i> , 2005, 45, 1207-1213.	2.7	27
124	Interactive Effects of Common $\beta$ 2 -Adrenoceptor Haplotypes and Age on Susceptibility to Hypertension and Receptor Function. <i>Hypertension</i> , 2005, 46, 301-307.	2.7	42
125	Pancreastatin: Multiple Actions on Human Intermediary Metabolism in Vivo, Variation in Disease, and Naturally Occurring Functional Genetic Polymorphism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5414-5425.	3.6	79
126	Common Genetic Mechanisms of Blood Pressure Elevation in Two Independent Rodent Models of Human Essential Hypertension. <i>American Journal of Hypertension</i> , 2005, 18, 633-652.	2.0	65



#	ARTICLE	IF	CITATIONS
127	Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. <i>Journal of Clinical Investigation</i> , 2005, 115, 1942-1952.	8.2	277
128	Genome-wide linkage analysis of chromogranin B expression in the CEPH pedigrees: implications for exocytotic sympathochromaffin secretion in humans. <i>Physiological Genomics</i> , 2004, 18, 119-127.	2.3	11
129	Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. <i>Physiological Genomics</i> , 2004, 19, 277-291.	2.3	80
130	The Catecholamine Release-Inhibitory $\alpha$ -Catestatin $\beta$ -Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses. <i>Molecular Pharmacology</i> , 2004, 66, 1180-1191.	2.3	86
131	A Dynamic Pool of Calcium in Catecholamine Storage Vesicles. <i>Journal of Biological Chemistry</i> , 2004, 279, 51107-51121.	3.4	51
132	Neuroendocrine Transcriptome in Genetic Hypertension. <i>Hypertension</i> , 2004, 43, 1301-1311.	2.7	37
133	Human sympathetic activation by $\beta$ 2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 139-153.	4.7	38
134	Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. <i>Regulatory Peptides</i> , 2004, 118, 75-87.	1.9	27
135	Both Rare and Common Polymorphisms Contribute Functional Variation at CHGA, a Regulator of Catecholamine Physiology. <i>American Journal of Human Genetics</i> , 2004, 74, 197-207.	6.2	104
136	Hereditary dysautonomias: current knowledge and collaborations for the future. <i>Clinical Autonomic Research</i> , 2003, 13, 180-195.	2.5	2
137	The Chromogranin $\beta$ -Secretogranin Family. <i>New England Journal of Medicine</i> , 2003, 348, 1134-1149.	27.0	770
138	Primary Sequence Characterization of Catestatin Intermediates and Peptides Defines Proteolytic Cleavage Sites Utilized for Converting Chromogranin A into Active Catestatin Secreted from Neuroendocrine Chromaffin Cells $\beta$ . <i>Biochemistry</i> , 2003, 42, 6938-6946.	2.5	33
139	Secretin Activation of Chromogranin A Gene Transcription. <i>Journal of Biological Chemistry</i> , 2003, 278, 19986-19994.	3.4	26
140	Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo. <i>Journal of Biological Chemistry</i> , 2003, 278, 32058-32067.	3.4	73
141	The angiotensin II receptor (Agtr1a): functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. <i>Physiological Genomics</i> , 2003, 14, 83-93.	2.3	16
142	Pharmacogenomics of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 61-70.	2.0	11
143	Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. <i>Journal of Cell Science</i> , 2002, 115, 4827-4841.	2.0	72
144	Chromaffin Cell Catecholamine Secretion: Bisindolylmaleimide Compounds Exhibit Novel and Potent Antagonist Effects at the Nicotinic Cholinergic Receptor in Pheochromocytoma Cells. <i>Molecular Pharmacology</i> , 2002, 61, 1340-1347.	2.3	7

#	ARTICLE	IF	CITATIONS
145	Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.. Journal of Hypertension, 2002, 20, 1335-1345.	0.5	182
146	Modulatory Mechanism of the Endogenous Peptide Catestatin on Neuronal Nicotinic Acetylcholine Receptors and Exocytosis. Journal of Neuroscience, 2002, 22, 377-388.	3.6	56
147	Neuroendocrine Cell Type-Specific and Inducible Expression of Chromogranin/Secretogranin Genes. Annals of the New York Academy of Sciences, 2002, 971, 27-38.	3.8	12
148	Intracellular Protein Trafficking into Catecholamine Storage Vesicles. Annals of the New York Academy of Sciences, 2002, 971, 262-265.	3.8	7
149	Studies of the Dysglycemic Peptide, Pancreastatin, Using a Human Forearm Model. Annals of the New York Academy of Sciences, 2002, 971, 528-529.	3.8	19
150	Malignant and Benign Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 971, 530-532.	3.8	20
151	The Catecholamine Release-Inhibitory -Catestatin-Region of Chromogranin A. Annals of the New York Academy of Sciences, 2002, 971, 533-535.	3.8	11
152	Neuroendocrine-Specific and Gastrin-Dependent Expression of a Chromogranin A-Luciferase Fusion Gene in Transgenic Mice. Gastroenterology, 2001, 121, 43-55.	1.3	13
153	Proteolytic Cleavage of Chromogranin A (CgA) by Plasmin. Journal of Biological Chemistry, 2001, 276, 25022-25029.	3.4	68
154	Formation of the Catecholamine Release-inhibitory Peptide Catestatin from Chromogranin A. Journal of Biological Chemistry, 2000, 275, 22905-22915.	3.4	67
155	Desensitization of Catecholamine Release. Journal of Biological Chemistry, 1999, 274, 2920-2928.	3.4	94
156	Catecholamine storage vesicle protein expression in genetic hypertension. Blood Pressure, 1999, 8, 285-295.	1.5	61
157	Dopamine $\beta$ -hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Human Genetics, 1998, 102, 533-540.	3.8	127
158	Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a $\beta$ -strand/loop/ $\beta$ -strand structure secured by hydrophobic interactions and predictive of activity. Regulatory Peptides, 1998, 77, 43-53.	1.9	39
159	Sp1 and CREB Mediate Gastrin-dependent Regulation of Chromogranin A Promoter Activity in Gastric Carcinoma Cells. Journal of Biological Chemistry, 1998, 273, 34000-34007.	3.4	64
160	Tissue Plasminogen Activator (t-PA) Is Targeted to the Regulated Secretory Pathway. Journal of Biological Chemistry, 1997, 272, 1976-1982.	3.4	148
161	A Novel, Catecholamine Release-Inhibitory Peptide from Chromogranin A: Autocrine Control of Nicotinic Cholinergic-Stimulated Exocytosis. Advances in Pharmacology, 1997, 42, 260-264.	2.0	15
162	Dispersion of Chromogranin/Secretogranin Secretory Protein Family Loci in Mammalian Genomes. Genomics, 1996, 33, 135-139.	2.9	30

#	ARTICLE	IF	CITATIONS
163	Hereditary intermediate phenotypes in African American hypertension. <i>Ethnicity and Health</i> , 1996, 1, 117-128.	2.5	17
164	Stimulus-transcription Coupling in Pheochromocytoma Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 28382-28390.	3.4	52
165	Vesicular Monoamine Transport Inhibitors. <i>Hypertension</i> , 1996, 28, 414-420.	2.7	32
166	Arterial Compliance by Cuff Sphygmomanometer. <i>Hypertension</i> , 1996, 28, 599-603.	2.7	44
167	Factitious pheochromocytoma: Novel mimicry by valsalva maneuver and clues to diagnosis*. <i>American Journal of Hypertension</i> , 1995, 8, 651-655.	2.0	16
168	Sympathoadrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release *. <i>Autonomic and Autacoid Pharmacology</i> , 1994, 14, 187-200.	0.6	57
169	Hormone Storage Vesicle Proteins.. <i>Annals of the New York Academy of Sciences</i> , 1994, 733, 36-45.	3.8	22
170	Assignment of the Chromogranin A (Chga) Locus to Homologous Regions on Mouse Chromosome 12 and Rat Chromosome 6. <i>Genomics</i> , 1993, 17, 252-255.	2.9	18
171	Chromogranin A as Tumor Marker in Medullary Thyroid Carcinoma. <i>Thyroid</i> , 1992, 2, 5-10.	4.5	41
172	Chromogranin a correlates with norepinephrine release rate. <i>Life Sciences</i> , 1992, 51, 519-525.	4.3	59
173	CSF chromogranin A-like immunoreactivity in schizophrenia: Relationships with REM latency and slow wave sleep. <i>Psychiatry Research</i> , 1992, 42, 53-63.	3.3	10
174	Pancreastatin-like immunoreactivity in human carcinoid disease. <i>Regulatory Peptides</i> , 1991, 33, 55-70.	1.9	34
175	Chromogranin B: isolation from pheochromocytoma, N-terminal sequence, tissue distribution and secretory vesicle processing. <i>Regulatory Peptides</i> , 1991, 33, 223-235.	1.9	23
176	Skin pretreatment and the use of transdermal clonidine. <i>American Journal of Medicine</i> , 1991, 91, S42-S49.	1.5	19
177	Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin a or basic fibroblast growth factor in ventricular fluid. <i>Experimental Neurology</i> , 1991, 111, 276-281.	4.1	11
178	Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. <i>Brain Research</i> , 1991, 567, 188-196.	2.2	34
179	CSF chromogranin A-like immunoreactivity in schizophrenia. <i>Schizophrenia Research</i> , 1991, 6, 31-39.	2.0	17
180	A Proposed Role for Chromogranin A as a Glucocorticoid-Responsive Autocrine Inhibitor of Proopiomelanocortin Secretion*. <i>Endocrinology</i> , 1991, 128, 1345-1351.	2.8	50

#	ARTICLE	IF	CITATIONS
181	Molecular Cloning, Structure, and Expression of Dopamine- $\beta$ -Hydroxylase from Bovine Adrenal Medulla. <i>Journal of Neurochemistry</i> , 1990, 55, 97-105.	3.9	18
182	Norepinephrine clearance, chromogranin A and dopamine $\beta$ hydroxylase in renal failure. <i>Kidney International</i> , 1990, 37, 1357-1362.	5.2	43
183	Chromogranin A in uremia: Progressive retention of immunoreactive fragments. <i>Kidney International</i> , 1990, 37, 955-964.	5.2	125
184	Plasma Norepinephrine Kinetics, Dopamine- $\beta$ -Hydroxylase, and Chromogranin-A, in Hypothyroid Patients before and following Replacement Therapy*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 277-281.	3.6	46
185	Chromogranin A in familial pheochromocytoma: Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. <i>American Journal of Medicine</i> , 1990, 88, 607-613.	1.5	79
186	Plasma Chromogranin-A in Primary Hyperparathyroidism*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 950-955.	3.6	22
187	How Sensitive and Specific Is Measurement of Plasma Chromogranin A for the Diagnosis of Neuroendocrine Neoplasia? a. <i>Annals of the New York Academy of Sciences</i> , 1987, 493, 379-386.	3.8	22
188	Secretion of Chromogranin A by Peptide-Producing Endocrine Neoplasms. <i>New England Journal of Medicine</i> , 1986, 314, 1145-1151.	27.0	464
189	Dopamine- $\beta$ -Hydroxylase: Structural Comparisons of Membrane-Bound Versus Soluble Forms from Adrenal Medulla and Pheochromocytoma. <i>Journal of Neurochemistry</i> , 1985, 44, 411-420.	3.9	24
190	The amino terminal sequences of bovine and human chromogranin A and secretory protein i are identical. <i>Biochemical and Biophysical Research Communications</i> , 1985, 127, 380-383.	2.1	36
191	Radioimmunoassay of Chromogranin a in Plasma as a Measure of Exocytotic Sympathoadrenal Activity in Normal Subjects and Patients with Pheochromocytoma. <i>New England Journal of Medicine</i> , 1984, 311, 764-770.	27.0	217
192	Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. <i>Regulatory Peptides</i> , 1983, 6, 263-280.	1.9	202
193	Chromogranin A: Immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. <i>Life Sciences</i> , 1983, 33, 1657-1663.	4.3	237
194	Preserved Renal Perfusion During Treatment of Essential Hypertension with the Beta Blocker Nadolol. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 187-195.	2.0	23
195	Renal hemodynamic changes during long-term antihypertensive therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 29, 310-317.	4.7	31
196	Reduced renovascular resistance by clonidine. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 572-577.	4.7	15
197	Recirculation: A Uremic Syndrome Complicating the use of Prosthetic Arteriovenous Fistulas for Hemodialysis. <i>Journal of Dialysis</i> , 1978, 2, 251-259.	0.4	14